Free Trial

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Bought by Woodline Partners LP

Fulcrum Therapeutics logo with Medical background

Woodline Partners LP lifted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 110.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,410,520 shares of the company's stock after acquiring an additional 739,713 shares during the period. Woodline Partners LP owned 2.61% of Fulcrum Therapeutics worth $6,629,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Fulcrum Therapeutics in the fourth quarter valued at approximately $38,000. Mariner LLC purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $78,000. Cantor Fitzgerald L. P. acquired a new position in Fulcrum Therapeutics during the fourth quarter worth approximately $94,000. Zacks Investment Management purchased a new stake in Fulcrum Therapeutics in the fourth quarter valued at approximately $99,000. Finally, Intech Investment Management LLC lifted its stake in Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after buying an additional 13,057 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on FULC shares. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research report on Thursday, May 15th. HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $12.00 in a research note on Friday, May 23rd. Finally, Leerink Partnrs upgraded Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Fulcrum Therapeutics has an average rating of "Hold" and an average target price of $5.83.

Read Our Latest Stock Analysis on FULC

Fulcrum Therapeutics Price Performance

Shares of FULC stock traded up $0.55 during mid-day trading on Wednesday, hitting $6.90. The stock had a trading volume of 997,779 shares, compared to its average volume of 970,585. The firm has a market cap of $372.46 million, a PE ratio of -22.26 and a beta of 2.29. The company's 50-day simple moving average is $4.16 and its 200-day simple moving average is $3.95. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Profile

(Free Report)

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

See Also

Institutional Ownership by Quarter for Fulcrum Therapeutics (NASDAQ:FULC)

Should You Invest $1,000 in Fulcrum Therapeutics Right Now?

Before you consider Fulcrum Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.

While Fulcrum Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines